Cost-effectiveness of the expansion of PrEP for HIV infection in the Asia Pacific region

Lancet Glob Health. 2024 Feb;12(2):e177-e178. doi: 10.1016/S2214-109X(23)00600-9.

Authors

Benjamin R Bavinton¹, Nila J Dharan²

Affiliations

¹ Kirby Institute, University of New South Wales Sydney, Sydney, NSW 2052, Australia.
² Kirby Institute, University of New South Wales Sydney, Sydney, NSW 2052, Australia. Electronic address: ndharan@kirby.unsw.edu.au.

PMID: 38245105
DOI: 10.1016/S2214-109X(23)00600-9

No abstract available

MeSH terms

Anti-HIV Agents* / therapeutic use
Asia / epidemiology
Cost-Benefit Analysis
HIV Infections* / drug therapy
HIV Infections* / epidemiology
HIV Infections* / prevention & control
Humans

Substances

Anti-HIV Agents